Embed Size (px)
DESCRIPTION
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
Citation preview
Wilbert Bannenberg
Technical Director
Concept and Structure of MeTA
21/7/2009
XXX
What is MeTA? A global alliance between:
– DFID, World Bank, WHO, private sector, civil society, professional organisations.
Multi-stakeholder collaboration– Government, CSOs and Private Sector
Working in 7 pilot countries to improve access to medicines. An International Secretariat to support country work, and, upon
request, technical assistance.
4/12/20093MeTA
MeTA hypothesis?
Cooperation and commitment by the 3 main stakeholder groups to disclose and jointly analyse data around the medicines supply chain will lead to better access to essential medicines
4/12/2009MeTA
4
Transparency? Improving information access, scrutiny and use, in order to support
the development of viable, efficient medicines markets and supply systems that benefit all developing country consumers– Transparency = not only disclosure of the price, quality, use,
availability of medicines; but also: – how to use the information to identify barriers, and to agree on
solutions
23/06/2009 MeTA
5
23/06/2009 MeTA
6
Key data collected in MeTA[Mainly through disclosures by stakeholders] Price data of medicines
– Procurement prices (~ MSH Intl price indicator)– Retail prices private, public sector (~WHO/HAI methodology)– Components (tax, VAT, margins, profit etc)
Quality and registration status– Medicines, GMP plants, GDP wholesalers, Licensed outlets
Availability (basket) Promotion (being developed)
…for each area:• Policy• Practices• Outcomes?
Contextual information collected
[From surveys rather than from disclosures] Supply chain operations
– Supply chain mapping data Affordability
– Generic utilization data, cost of treatment (related to salary) Equitable access
– Data on health and medicines expenditure by income group, and experiences of treating key illnesses by income group.
Rational use– Household survey data, prescribing data in health facilities
23/06/2009 MeTA
7
Who should disclose what? Government: VAT, taxes, budget, selection, quantification, Procurement agency: purchase & selling prices DRA: quality and registration data, inspection, QC lab results Private sector: prices, margins, availability, promotion codes of
conduct Civil society / academics: Availability (equity), Affordability, Rational
use
23/06/2009 MeTA
8
What should this lead to?
Better information to the sector & general public More engagement in MeTA Councils All stakeholders better informed More trust and collaboration between stakeholders Seeking improved, joint solutions Better access to medicines
– Key hypothesis to be proven!
23/06/2009 MeTA
9
1. Responsibility for access
Governments are responsible for providing access to health care, including access to essential medicines
05/09/2009
3MeTA FIP
2. Role of transparency
Stronger and more transparent systems and improved supply chain management will increase access
05/09/2009
3MeTA FIP
3. Equity
Increasing equitable access to medicines improves health and enables other human development objectives to be achieved
05/09/2009
4MeTA FIP
4. Evidence-based policy
Improved information about medicines can inform public debate, and provide a basis for better policy
05/09/2009
6
2. Affordableprices
ACCESS
1. Rationalselection
4. Reliablehealth and
supply systems
3. Sustainablefinancing
MeTA FIP
5. Mutual accountability through mutli-stakeholder action
A multi-stakeholder approach that involves all sectors – private, public and civil society - will lead to greater accountability
05/09/2009
7MeTA FIP
XXXX
21/7/2009
MeTA Structure
Pilot Country National Stakeholder Forums, each with a Secretariat,
The International Secretariat
A Management Board (consisting of UK's DFID, which chairs the Board, the World Health Organization and the World Bank)
An International Advisory GroupDFID, WHO, WB, Private Sector, Academia, Pilot Country reps
.
MeTA Core Principles Governments are responsible for providing access
to health care, including access to essential medicines Stronger and more transparent systems and
improved supply chain management will increase access
increasing equitable access to medicines improves health and enables other human development objectives to be achieved
Improved information about medicines can inform public debate, and provide a basis for better policy
A multi-stakeholder approach that involves all sectors – private, public and civil society - will lead to greater accountability
MeTA’s goal MeTA’s overall goal is to increase access to
essential medicines for the poorest of the poor in developing countries
XX
4/12/2009MeTA 20
MeTA hypothesis?
Cooperation and commitment by the 3 main stakeholder groups to disclose and jointly analyse data around the medicines supply chain will lead to better access to essential medicines
Page 21
The MeTA Pilot
New validated data on pharmaceutical sector
Disclosure of data and scrutiny by multi-stakeholder group
Development of policy options
Policy change and implementation
Changes in drug prices, availability, quality and/or promotion
Improved information for management
Improved processes.
New validated data on pharmaceutical sector
New validated data on pharmaceutical sector
Disclosure of data and scrutiny by multi-stakeholder group
Development of policy options
Policy change and implementation
Changes in drug prices, availability, quality and/or promotion
Changes in drug prices, availability, quality and/or promotion
Improved information for management
Improved processes.
Pilot
££, toolkit & technical support
Policy research, shared learning
Sector plans, domestic and CPs
